Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nivolumab - Bristol-Myers Squibb/Ono Pharmaceuticals

Drug Profile

Nivolumab - Bristol-Myers Squibb/Ono Pharmaceuticals

Alternative Names: BMS-936558; MDX-1106; Nivolumab BMS; ono-0123; ONO-4538; Opdivo

Latest Information Update: 11 Dec 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Medarex; Ono Pharmaceutical; Sidney Kimmel Cancer Center
  • Developer Aduro BioTech; AIO Studien gGmbH; Australian and New Zealand Urogenital and Prostate Cancer Group; Barbara Ann Karmanos Cancer Institute; Bavarian Nordic; Big Ten Cancer Research Consortium; Bristol-Myers Squibb; Canadian Cancer Trials Group; Celleron Therapeutics; Clovis Oncology; Curie Institute; Daiichi Sankyo Company; Dana-Farber Cancer Institute; Duke University Medical Center; Eisai Inc; Eli Lilly; Emory University; European Thoracic Oncology Platform; Exelixis; Frontier Science foundation; Grupo Espanol Multidisciplinar de Melanoma; H. Lee Moffitt Cancer Center and Research Institute; Hoosier Cancer Research Network; HOVON Foundation; Incyte Corporation; Intergroupe Francophone de Cancerologie Thoracique; Janssen Biotech; Janssen Research & Development; Kansai Medical University; Kyoto Breast Cancer Research Network; M. D. Anderson Cancer Center; Massachusetts General Hospital; Medarex; Nantes University Hospital; National Cancer Center (Tokyo); National Cancer Centre (Singapore); National Cancer Institute (USA); Nektar Therapeutics; Neon Therapeutics; Netherlands Cancer Institute; Northwestern University; Ono Pharmaceutical; Pharmacyclics; PrECOG; Seattle Genetics; Sidney Kimmel Cancer Center; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Syneos Health; The University of Montreal Hospital Research Center; UNICANCER; University College London; University of Liverpool; University of Pittsburgh; University of Texas M. D. Anderson Cancer Center; Zucero Therapeutics
  • Class Antineoplastics; Antivirals; Monoclonal antibodies
  • Mechanism of Action Programmed cell death-1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mesothelioma; Malignant melanoma; Liver cancer; Hodgkin's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Colorectal cancer; Gastric cancer; Head and neck cancer; Hodgkin's disease; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Urogenital cancer
  • Registered Liver cancer; Mesothelioma; Small cell lung cancer
  • Phase III Fallopian tube cancer; Glioblastoma; Multiple myeloma; Oesophageal cancer; Ovarian cancer; Peritoneal cancer
  • Phase II/III Non-Hodgkin's lymphoma
  • Phase II Acute myeloid leukaemia; Adrenocortical carcinoma; Biliary cancer; Bladder cancer; Brain metastases; Breast cancer; Cancer; Cervical cancer; Cholangiocarcinoma; Chronic lymphocytic leukaemia; CNS cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Genitourinary disorders; Liver metastases; Meningeal carcinomatosis; Myelodysplastic syndromes; Nasopharyngeal cancer; Oropharyngeal cancer; Pancreatic cancer; Penile cancer; Prostate cancer; Soft tissue sarcoma; Solid tumours; Testicular cancer; Thyroid cancer; Uterine cancer; Uveal melanoma
  • Phase I/II Haematological malignancies; Rectal cancer; Sepsis
  • Phase I Chronic myeloid leukaemia; Glioma; Hepatitis C

Most Recent Events

  • 05 Dec 2018 Gilead Sciences plans a phase Ib trial for Hepatitis B in Hong Kong and New Zealand (ACTRN12618001843246p)
  • 01 Dec 2018 Adverse events and efficacy data from a phase I/II trial in Hodgkin's disease released by Seattle Genetics
  • 01 Dec 2018 Adverse events data from the phase III Checkmate-744 in Hodgkin's disease released by Seattle Genetics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top